33rd Annual CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow^®

Click here to download brochure

Overview

State-of-the-art cancer care continues to evolve due to advances in all aspects of patient care - including diagnosis, and personalized treatment and management. Through the incorporation of novel diagnostics, systemic therapies, molecular targeted therapies, immunotherapies, and other biotechnological strategies into treatment paradigms, patient outcomes continue to improve along the cancer continuum. The annual CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow^®, has brought together over 2,000 oncologists, hematologists, radiation oncologists, immunologists, oncology nurses, nurse practitioners, physician assistants, and case managers each year for 32 years, with the aim of educating these disciplines on state-of-the-art treatments across solid and hematologic malignancies and diverse clinical scenarios. At the 33rd Annual CFS™ Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow^®, our outstanding faculty of leading clinical innovators in virtually every tumor subspecialty will continue to provide expert insights on new developments in cancer therapeutics, and provide oncology professionals with the opportunity to learn about new compounds, novel approaches to diagnosis and treatment with currently available agents, ongoing clinical trials, and emerging developments that define current progress aimed at the goal of control and cure of cancer.

Target Audience

This educational program is directed toward oncologists and hematologists interested in the treatment of patients with cancer. Radiotherapists, immunologists, fellows, nurse practitioners, nurses, physician assistants, researchers, case managers, and other health care professionals interested in the treatment of cancer are also invited to attend. 

Program Co-Chairs

Steering Committee

Kimberly L. Blackwell, MD
Medical Oncologist
Duke Cancer Center
Durham, NC



C. Ola Landgren, MD, PhD
Hematologic Oncologist
Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY


Jason J. Luke, MD
Medical Oncologist
Assistant Professor of Medicine
University of Chicago Medicine
Chicago, IL


John L. Marshall, MD
Chief, Division of Hematology/Oncology
Georgetown University Hospital
Associate Director, Clinical Research
Lombardi Comprehensive Cancer Center
Washington, DC

William K. Oh, MD
Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine at Mount Sinai
Associate Director, Clinical Research
The Tisch Cancer Institute
New York, NY

Naiyer Rizvi, MD
Director, Thoracic Oncology
Director, Immunotherapeutics
Price Chair, Clinical Translational Research
Columbia University Medical Center
New York, NY

 

Agenda Highlights